| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2013-05-17 01:26:04 UTC |
|---|
| Update Date | 2021-09-14 15:42:58 UTC |
|---|
| HMDB ID | HMDB0060510 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | SN-38 |
|---|
| Description | 7-Ethyl-10-hydroxycamptothecin (SN38) is the active metabolite of irinotecan (an analog of camptothecin - a topoisomerase I inhibitor); it is 1000 times more active than irinotecan itself. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold. SN38 is metabolized via glucoronidation by UGT1A1. (Wikipedia ) 7-Ethyl-10-hydroxycamptothecin (SN38), the active metabolite of irinotecan, exerts a 100-fold to 1000-fold higher effect than irinotecan itself against several tumor cell lines. (PMID: 23233044 ) Among five chemotherapeutic agents commonly used for breast cancer treatment, only an irinotecan metabolite SN38 showed additive antitumor activity with olaparib. (PMID: 22454224 ) Metabolism of irinotecan to SN38 is inefficient and subject to considerable patient-to-patient variability. One approach to more controlled administration of the anticancer agent is direct administration of the active SN38. (PMID: 23299391 ) |
|---|
| Structure | CCC1=C2C=C(O)C=CC2=NC2=C1CN1C2=CC2=C(COC(=O)[C@]2(O)CC)C1=O InChI=1S/C22H20N2O5/c1-3-12-13-7-11(25)5-6-17(13)23-19-14(12)9-24-18(19)8-16-15(20(24)26)10-29-21(27)22(16,28)4-2/h5-8,25,28H,3-4,9-10H2,1-2H3/t22-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 10-Hydroxy-7-ethylcamptothecin | ChEBI | | 7-Ethyl-10-hydroxy-20(S)-camptothecin | ChEBI | | 7-Ethyl-10-hydroxycamptothecin | ChEBI | | sn 38 | ChEBI | | sn 38 Lactone | ChEBI | | CPT 11 | HMDB | | Camptosar | HMDB | | Irrinotecan | HMDB | | Camptothecin-11 | HMDB | | Irinotecan hydrochloride | HMDB | | CPT-11 | HMDB | | sn38 CPD | HMDB | | Irinotecan | HMDB | | NK012 Compound | HMDB | | CPT11 | MeSH | | 7 Ethyl 10 hydroxycamptothecin | MeSH | | Camptothecin 11 | MeSH |
|
|---|
| Chemical Formula | C22H20N2O5 |
|---|
| Average Molecular Weight | 392.4046 |
|---|
| Monoisotopic Molecular Weight | 392.13722176 |
|---|
| IUPAC Name | (19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione |
|---|
| Traditional Name | 7-ethyl-10-hydroxycamptothecin |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CCC1=C2C=C(O)C=CC2=NC2=C1CN1C2=CC2=C(COC(=O)[C@]2(O)CC)C1=O |
|---|
| InChI Identifier | InChI=1S/C22H20N2O5/c1-3-12-13-7-11(25)5-6-17(13)23-19-14(12)9-24-18(19)8-16-15(20(24)26)10-29-21(27)22(16,28)4-2/h5-8,25,28H,3-4,9-10H2,1-2H3/t22-/m0/s1 |
|---|
| InChI Key | FJHBVJOVLFPMQE-QFIPXVFZSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as camptothecins. These are heterocyclic compounds comprising a planar pentacyclic ring structure, that includes a pyrrolo[3,4-beta]-quinoline moiety (rings A, B and C), conjugated pyridone moiety (ring D) and one chiral center at position 20 within the alpha-hydroxy lactone ring with (S) configuration (the E-ring). |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Alkaloids and derivatives |
|---|
| Class | Camptothecins |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Camptothecins |
|---|
| Alternative Parents | |
|---|
| Substituents | - Camptothecin
- Hydroxyquinoline
- Pyranopyridine
- Quinoline
- 1-hydroxy-2-unsubstituted benzenoid
- Pyridinone
- Pyridine
- Benzenoid
- Heteroaromatic compound
- Tertiary alcohol
- Carboxylic acid ester
- Lactam
- Lactone
- Azacycle
- Organoheterocyclic compound
- Carboxylic acid derivative
- Oxacycle
- Monocarboxylic acid or derivatives
- Organic nitrogen compound
- Alcohol
- Organic oxygen compound
- Carbonyl group
- Organonitrogen compound
- Organooxygen compound
- Organopnictogen compound
- Organic oxide
- Hydrocarbon derivative
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 6.17 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.971 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.07 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2376.0 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 176.4 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 144.4 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 134.7 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 143.1 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 479.4 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 442.8 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 70.6 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 764.7 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 434.0 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1510.5 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 267.8 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 270.7 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 201.5 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 129.4 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 49.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| SN-38,1TMS,isomer #1 | CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(O[Si](C)(C)C)C=C12 | 3592.1 | Semi standard non polar | 33892256 | | SN-38,1TMS,isomer #2 | CCC1=C2CN3C(=CC4=C(COC(=O)[C@@]4(CC)O[Si](C)(C)C)C3=O)C2=NC2=CC=C(O)C=C12 | 3562.9 | Semi standard non polar | 33892256 | | SN-38,2TMS,isomer #1 | CCC1=C2CN3C(=CC4=C(COC(=O)[C@@]4(CC)O[Si](C)(C)C)C3=O)C2=NC2=CC=C(O[Si](C)(C)C)C=C12 | 3538.1 | Semi standard non polar | 33892256 | | SN-38,1TBDMS,isomer #1 | CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(O[Si](C)(C)C(C)(C)C)C=C12 | 3808.4 | Semi standard non polar | 33892256 | | SN-38,1TBDMS,isomer #2 | CCC1=C2CN3C(=CC4=C(COC(=O)[C@@]4(CC)O[Si](C)(C)C(C)(C)C)C3=O)C2=NC2=CC=C(O)C=C12 | 3761.8 | Semi standard non polar | 33892256 | | SN-38,2TBDMS,isomer #1 | CCC1=C2CN3C(=CC4=C(COC(=O)[C@@]4(CC)O[Si](C)(C)C(C)(C)C)C3=O)C2=NC2=CC=C(O[Si](C)(C)C(C)(C)C)C=C12 | 3934.8 | Semi standard non polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - SN-38 GC-MS (Non-derivatized) - 70eV, Positive | splash10-0cds-0019000000-79b6acd0ac5020e4fdae | 2017-09-20 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - SN-38 GC-MS (2 TMS) - 70eV, Positive | splash10-0200-4001940000-c0a3b0dcc77abbfdfa52 | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - SN-38 GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - SN-38 10V, Positive-QTOF | splash10-0006-0019000000-953c13d44f1f753e244d | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - SN-38 20V, Positive-QTOF | splash10-000f-0049000000-3bc00f235d1656474cea | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - SN-38 40V, Positive-QTOF | splash10-000i-0090000000-0c561151ab4c396125a0 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - SN-38 10V, Negative-QTOF | splash10-0006-0009000000-1a6f7a9c5371b8ce6492 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - SN-38 20V, Negative-QTOF | splash10-0005-0009000000-2782aeafd6952cc625f1 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - SN-38 40V, Negative-QTOF | splash10-004r-1092000000-87d95d0b42a2bf62be7e | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - SN-38 10V, Positive-QTOF | splash10-0006-0009000000-d961fc5bd50f1cdfa8f1 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - SN-38 20V, Positive-QTOF | splash10-002f-0009000000-ba15d6f829920d4c5f91 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - SN-38 40V, Positive-QTOF | splash10-0006-0198000000-d61425ae38337cad41b5 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - SN-38 10V, Negative-QTOF | splash10-0006-0009000000-2c62dc28c202dd25256d | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - SN-38 20V, Negative-QTOF | splash10-01ox-0009000000-088053c8ac6be94eaf25 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - SN-38 40V, Negative-QTOF | splash10-000i-0349000000-d2fa036a90b6e5d04a1c | 2021-10-12 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Magrane M: UniProt Knowledgebase: a hub of integrated protein data. Database (Oxford). 2011 Mar 29;2011:bar009. doi: 10.1093/database/bar009. Print 2011. [PubMed:21447597 ]
- Sostelly A, Payen L, Guitton J, Di Pietro A, Falson P, Honorat M, Boumendjel A, Geze A, Freyer G, Tod M: Quantitative evaluation of the combination between cytotoxic drug and efflux transporter inhibitors based on a tumour growth inhibition model. Fundam Clin Pharmacol. 2014 Apr;28(2):161-9. doi: 10.1111/fcp.12005. Epub 2013 Feb 6. [PubMed:23384250 ]
- Yao Y, Su X, Xie Y, Wang Y, Kang T, Gou L, Yi C, Yang J: Synthesis, characterization, and antitumor evaluation of the albumin-SN38 conjugate. Anticancer Drugs. 2013 Mar;24(3):270-7. doi: 10.1097/CAD.0b013e32835c3543. [PubMed:23233044 ]
- Sostelly A, Payen L, Guitton J, Di Pietro A, Falson P, Honorat M, Valdameri G, Geze A, Boumendjel A, Freyer G, Tod M: A template model for studying anticancer drug efflux transporter inhibitors in vitro. Fundam Clin Pharmacol. 2013 Oct;27(5):544-56. doi: 10.1111/j.1472-8206.2012.01054.x. Epub 2012 Aug 8. [PubMed:22882086 ]
- Shimo T, Kurebayashi J, Kanomata N, Yamashita T, Kozuka Y, Moriya T, Sonoo H: Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells. Breast Cancer. 2014 Jan;21(1):75-85. doi: 10.1007/s12282-012-0356-z. Epub 2012 Mar 28. [PubMed:22454224 ]
- Al-Kasspooles MF, Williamson SK, Henry D, Howell J, Niu F, Decedue CJ, Roby KF: Preclinical antitumor activity of a nanoparticulate SN38. Invest New Drugs. 2013 Aug;31(4):871-80. doi: 10.1007/s10637-012-9919-2. Epub 2013 Jan 9. [PubMed:23299391 ]
|
|---|